Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
Engineered Salmonella secreting heterologous bacterial flagellin suppress tumor growth by activating intratumoral macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
From The microbiome and human cancer (2021) · cites this paper as [152]
Citations
Cites
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“INTRODUCTION Abnormal blood vessels and hypoxic and necrotic regions are universal features of solid tumors (1, 2).”
BackgroundKigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130 · cited 1×
“The engrafted MC38 tumor tissues were removed from C57BL/6 WT mice 24 hours after induction of FlaB and triple-stained with CD45, F4/80, and CD206 (to detect M2-type macrophages) or with CD45, F4/80, and CD86 (to detect M1-type macrophages) (32, 33).”
MethodTargeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041 · cited 1×
“TLR4, TLR5, and MyD88 knockout mice with a C57BL/6 genetic background were described previously (47, 48).”
MethodMolecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980 · cited 10×
“The in vitro stimulation of cancer cells with FlaB did not increase phosphorylation of NF-kB p65 (fig.”
BackgroundInfluentialThe Isolation and Characterization of Murine Macrophages
Zhang, X., Goncalves, R., & Mosser, D. M. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im1401s83 · Cited by 1,536 · cited 1×
“Cell preparation and FACS analysis Peritoneal macrophages were isolated from specific pathogen–free C57BL/6 male mice, as described previously (50).”
MethodToll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 1×
“Because the background signals in experimental groupswere different, whichmay be due to different degrees of cell injury resulting from the different modes of treatment (PBS, empty Salmonella, and FlaB-secreting Salmonella), we adjusted gating parameters for the FACS analysis of different groups (51, 52).”
MethodTherapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Because of accumulating reports that activating various TLRs resulted in antitumor effects (31, 37–41), many TLRspecific agonists are currently being investigated for tumor immunotherapy (37).”
BackgroundBiswas, S. K. (2006) · Blood · doi:10.1182/blood-2005-01-0428 · Cited by 696
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“VNP20009, an attenuated strainof Salmonella typhimurium with purI and msbB gene deletions, was safely administered to patients with metastatic melanoma and renal cell carcinoma in a phase 1 study, where substantial tumor colonization was observed (11, 12).”
Research works printed but not linked: 1
- 10.1200/jco.2002.20.1.142 · DOI · Paper page
Cited by
Items 601–627 of 627
Jinhu, G., Li, Y., Yang, Y., & Wang, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1878878
“…that Salmonella Typhimurium modi fi ed to express heterologous fl agellin B (FlaB) from Vibrio vulni fi cus, as well as attenuated Listeria monocytogenes , exert anti-tumor effects by inducing a phenotypic shift from immunosuppressive M2 to pro-in fl ammatory M1 macrophages in the TME (139, 180).”
Nguyen, D.-H., Afzal, A. R., Nguyen, P. T.-M., Do-Ba, Q.-T., Nguyen, K. V., Lee, W.-S., Min, J.-J., & Hong, Y. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03300-x
Self-citationOliva, G., Ahmed, S., Shao, M., Mekalanos, J. J., & Brenner, G. J. (2026) · mBio · doi:10.1128/mbio.01275-26
“Excised tumors were processed and plated on LB agar to determine bacterial load (CFU/g) as previously described (8).”
Shen, H., Zhang, W., Niu, G., Wang, L., Li, R., Fan, Y., Lu, F., Xu, L., Ji, X., & Kang, Y. (2026) · BMEMat · doi:10.1002/bmm2.70130
Harnessing colorectal tumour enriched glutamate to improve E. coli Nissle tumour specificity
de Nys, R., Foschini, S., Barratt, K. R., Hasan, S. T., Leeflang, J., Trim, P. J., Menelaou, A., Snel, M. F., Radford, G., Silva, T. N., et al. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-026-01139-9
Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy
Feng, Q., Wang, C., Li, Z., Sheng, D., Shi, S., Liu, J., & Chen, B. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103016
Lu, J., Xuan, M., Yu, L., Xie, Z., Chu, Q., Wei, S., Wang, T., Xue, C., & Li, L. (2026) · MedComm · doi:10.1002/mco2.70994
“Attenuated Salmonella typhimurium has been used to increase 5-FU levels within tumors or reshape tumor-associated macrophage phenotypes by releasing Vibrio vulnificus flagellin B [ 227, 421 ].”
Wu, Y., Wang, M., Li, T., Huang, Z., Wu, M., Sun, T., & Cong, H. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s630802
“22,65 Bacterial examples include attenuated Salmonella typhimurium, leveraging flagellar motility and chemotaxis to target neuroinflammation, 66 with autolysis triggered by low Mg 2+ to release CRISPR–Cas9 under inflammation-sensitive promoters.”
The emerging role of microbiota in neuro-oncology
Morad, G., Soto, R. A., Ajami, N. J., Ferguson, S. D., & Wargo, J. A. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01266-z
Establishing Management Framework for Biosafety Risk Assessments of Synthetic Biology
Zuo, K., Lu, Q., 李纪元, Yan, S., Xiang, Q., Zhang, L., Lei, R., & Liu, H. (2026) · Laboratories · doi:10.3390/laboratories3040024
Empowering cancer therapy: the promise of natural adjuvants
De, T., Bibi, R., & Sarkar, K. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12800-z
Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy
Tian, T., & Chen, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1956198
“Beyond delivering antibacterial agents to regulate ITM, nano-technology can remodel the TIME and enhance ICB ef fi cacy.”
InfluentialIntratumoral Microbiota in Fueling Cancer and Steering Treatment Response
Xu, M., Yu, J., Chen, Y., Ge, S., Ye, L., Wang, Y., 周一雄, & Jia, R. (2026) · MedComm · doi:10.1002/mco2.71052
Hou, X., Guo, P., Wang, S., Yuan, Y., Wei, W., & Zheng, D. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100599
Wang, L., Chen, Y., Shang, Y., Liu, J., Zhao, M., Jin, L., Shi, Y., Zhang, R., Chen, Z., Yin, T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103111
Yongjie, Z., Cheng, M., 刘金玲, Xiong, M., Lan, J., Han, K., Yi, S., Jiang, S., Tan, W., & Zheng, J. H. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.036
Self-citationElmetwalli, A., Algehainy, N. A., Altemani, F. H., Alanazi, M. A., & Altemani, A. H. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127586
Liang, Y., Ning, Z., Su, B., Liang, N., Zhu, F., & Sun, T. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111354
Camillo, L., Alexandrino, A. V., Rodolpho, J. M. A., Fragelli, B. D. L., Novo-Mansur, M. T. M., Silva, A. J., & Aníbal, F. F. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109061
Zhou, L., Qian, Z., Yao, R., Chen, C., Pan, P., Guo, Z., Xu, Z., Mei, Y., & Wang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1972278
Wang, J., Qi, R., Chang, T., & Zhang, Y. (2026) · Engineering Microbiology · doi:10.1016/j.engmic.2026.100311
El-Sherbiny, G. M. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189748
Laryngeal Cancer Microbiome Study Reveals Parvimonas and Campylobacter as Potential Therapy Targets
Lad, H., Shah, A., Thompson, E. R., Javid, S., Chee, R. H., Zaransky, S., Dhanda, A. K., Mudhar, A., Lamichhane, S., Chua, A. T., et al. (2026) · The Laryngoscope · doi:10.1002/lary.71027
Dong, L., Song, Y., Li, X., Wu, J., Luo, X., Du, Y., & Xu, T. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105698
Advances in the design, mechanism and clinical translation of engineered bacteria in cancer therapy
Fu, H., 廖翔宇, Wang, Y., Ye, H., & Tian, J. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026207
The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications
Zhang, X., Lou, N., Dong, J., Li, H., Wang, N., Li, Y., & Han, X. (2026) · MedComm · doi:10.1002/mco2.71133
Raveendran, S., Shetty, V., & Shetty, S. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108930
Metadata
- Authors
- Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., Choy, H. E., Lee, S. E., Rhee, J. H., & Min, J.-J.
- Affiliations
- Chonnam National University (KR)
- City Of Hope National Medical Center (US)
- Department of Nuclear Medicine, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Corresponding author
- Rhee, Joon Haeng
- Min, Jung-Joon
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-08
- Volume
- 9
- Issue
- 376
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2586223583
- Cited by
- 588
- References
- 54
- Citations by year
- 2026: 76 · 2025: 81 · 2024: 85 · 2023: 73 · 2022: 71 · 2021: 65 · 2020: 55 · 2019: 34 · 2018: 30 · 2017: 18
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- KRIBB Repository (submittedVersion)
- Funders
- Pioneer Research Center Program (2015M3C1A3056410)
- Bio & Medical Technology Development Program (NRF-2014M3A9B5073747)
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
- NRF (2012-0006072)
- Ministry of Health and Welfare, Republic of Korea (HI14C0187)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunotherapy, Salmonella typhimurium, tumor-targeting bacteria, intratumoral macrophages, M1 macrophage polarization, TLR ligands
- MeSH terms
- Animals, Colonic Neoplasms, Flagellin, Genetic Engineering, Humans, Immunotherapy, Macrophages, Male, Mice, Inbred C57BL, Mice, Nude, Neoplasm Metastasis, Neoplasms, Phenotype, Salmonella typhimurium, Colony Count, Microbial, Signal Transduction, Cell Polarity, Xenograft Model Antitumor Assays, HCT116 Cells, Toll-Like Receptor 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.